| Aaron Robert Furchner, PA | |
|
2800 10th Ave N, Billings, MT 59101-0799 | |
| (406) 238-2500 | |
| Not Available |
| Full Name | Aaron Robert Furchner |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 4 Years |
| Location | 2800 10th Ave N, Billings, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174103063 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | MED-PAC-LIC-91639 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Billings Clinic | Billings, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Billings Clinic | 6002993516 | 659 |
News Archive
Capstone Therapeutics announced today that participating subjects have reached the planned twelve-month timepoint in the first of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. Data analysis for these subjects is underway. Per protocol and the original clinical development plan, results of the two keloid scarring trials will be pooled for analytical purposes and are scheduled for release during 4Q2010.
The College of American Pathologists, the American Society for Clinical Pathology, and the American Society of Clinical Oncology today released an evidence-based clinical practice guideline on human epidermal growth factor receptor 2 (HER2) testing for patients with gastroesophageal cancers.
AlphaCore Pharma, a biopharmaceutical company developing ACP-501 (rhLCAT) for the treatment of high risk atherosclerosis and serious lipid metabolism disorders, today announced the initiation of a Phase 1 study of ACP-501 in patients with stable coronary arterial disease.
Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison- (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in improving suboptimal echocardiograms.
With their potential to treat a wide range of diseases and uncover fundamental processes that lead to those diseases, embryonic stem (ES) cells hold great promise for biomedical science.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Aaron Robert Furchner, PA 2800 10th Ave N, Billings, MT 59101-0799 Ph: (406) 238-2500 | Aaron Robert Furchner, PA 2800 10th Ave N, Billings, MT 59101-0799 Ph: (406) 238-2500 |
News Archive
Capstone Therapeutics announced today that participating subjects have reached the planned twelve-month timepoint in the first of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. Data analysis for these subjects is underway. Per protocol and the original clinical development plan, results of the two keloid scarring trials will be pooled for analytical purposes and are scheduled for release during 4Q2010.
The College of American Pathologists, the American Society for Clinical Pathology, and the American Society of Clinical Oncology today released an evidence-based clinical practice guideline on human epidermal growth factor receptor 2 (HER2) testing for patients with gastroesophageal cancers.
AlphaCore Pharma, a biopharmaceutical company developing ACP-501 (rhLCAT) for the treatment of high risk atherosclerosis and serious lipid metabolism disorders, today announced the initiation of a Phase 1 study of ACP-501 in patients with stable coronary arterial disease.
Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison- (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in improving suboptimal echocardiograms.
With their potential to treat a wide range of diseases and uncover fundamental processes that lead to those diseases, embryonic stem (ES) cells hold great promise for biomedical science.
› Verified 1 days ago
Kirk Kenfield, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Alexander Ramsey, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Kaitlyn Steele, PA-C Physician Assistant Medicare: May Accept Medicare Assignments Practice Location: 1611 Zimmerman Trl, Billings, MT 59102 Phone: 406-248-3607 | |
Trenay Hart, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1233 N 30th St, Billings, MT 59101 Phone: 406-237-4141 Fax: 406-237-4126 | |
Melanie Schmitz, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Jamaica Rachel Moore, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 801 North 29th Street, Billings Clinic, Billings, MT 59101 Phone: 406-238-2410 | |
Kortney Ann Gaughan, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 2900 12th Ave N Ste 160w, Billings, MT 59101 Phone: 406-237-4580 |